Korn, Stephanie
Howarth, Peter
Smith, Steven G.
Price, Robert G.
Yancey, Steven W.
Prazma, Charlene M.
Bel, Elisabeth H.
Funding for this research was provided by:
gsk
Article History
Received: 30 June 2021
Accepted: 14 February 2022
First Online: 4 March 2022
Declarations
:
: Not applicable as this is a descriptive review of trial design.
: Not applicable.
: SK reports personal fees and grants from AstraZeneca, GSK, Novartis and Sanofi. EHB has received grants for research from GSK and Teva, consulting fees from AstraZeneca, Chiesi, GSK, Novartis, and Sanofi/Regeneron, and fees for participation in advisory boards from AstraZeneca, Chiesi, GSK, Novartis, Sanofi/Regeneron, and Sterna. PH, SGS, RGP, SWY and CMP are employed by GSK and own stocks/shares.